




>>Entry Name: **Mopidamol**, BAN, INN

Synonym(s): 2,2',2'',2'''-[[[4-Piperidiny]pyrimido[5,4-*d*]pyrimidine-2,6-diyl]dinitrilo]tetrakis[ethanol], 9Cl, 8Cl. 2,6-Bis[*N,N*-bis(2-hydroxyethyl)amino]-4-piperidinopyrimido[5,4-*d*]pyrimidine. Repentone. Rapenton. R-A 233-BS



CAS Registry Number: 13665-88-8

Molecular Formula: C₁₉H₃₁N₇O₄

Molecular Weight: 421.498

Accurate Mass: 421.243753

Percentage Composition: C 54.14%; H 7.41%; N 23.26%; O 15.18%

Use/Importance: Platelet aggregation inhibitor. Inhibits tumour metastases

Physical Description: Yellow cryst.

Melting Point: Mp 166-172°. Mp 157-158°

Calculated Log P Data: Log P -0.11 (calc)

Other Data: Analogue of Dipyridamole [FLV85-D](#)

Hazard & Toxicity: LD₅₀ (rat, orl) 3000 mg/kg

References:

- U.K. Pat.*, 1966, *Dr Karl Thomae*, 1 051 218; *CA*, **66**, 55521p, (*synth, pharmacol*)
U.S. Pat., 1967, *Boehringer Ingelheim*, 3 322 755; *CA*, **68**, 69048t, (*synth, pharmacol*)
Koch, H., *Drugs of Today (Barcelona)*, 1981, **17**, 89, (*pharmacol, tox, rev*)
Zacharski, L.R. *et al.*, *J. Natl. Cancer Inst.*, 1988, **80**, 90; 532, (*clin trial*)
Tzanakakis, G.N. *et al.*, *Cancer (Philadelphia)*, 1993, **71**, 2466, (*pharmacol*)
De la Cruz, J.P. *et al.*, *Biochem. Pharmacol.*, 1994, **47**, 209, (*pharmacol*)
De la Cruz, J.P. *et al.*, *Gen. Pharmacol.*, 1996, **27**, 855, (*pharmacol*)
Martindale, The Extra Pharmacopoeia, 31st edn., Pharmaceutical Press, 1996, 591